Robert W. Baird Cuts Humana (NYSE:HUM) Price Target to $297.00

Key Points

• Robert W. Baird has cut its price target for Humana from $300.00 to $297.00, maintaining a "neutral" rating on the stock.
• The current average consensus target price for Humana is $282.43, with 16 investment analysts rating the stock as a hold and 8 as a buy.
• Humana's stock is currently down 3.2%, opening at $229.48, after having a 1-year high of $406.09.

Humana (NYSE:HUM - Get Free Report) had its price target cut by investment analysts at Robert W. Baird from $300.00 to $297.00 in a report released on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the insurance provider's stock. Robert W. Baird's price target would indicate a potential upside of 29.42% from the stock's current price.

Several other research analysts have also recently weighed in on the company. Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a research note on Sunday, July 20th. Barclays set a $268.00 price target on Humana and gave the stock an "equal weight" rating in a research note on Thursday, June 12th. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Truist Financial reduced their price objective on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Finally, Mizuho upped their price objective on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $282.43.

Humana Stock Down 3.2%

HUM stock opened at $229.48 on Friday. Humana has a 1-year low of $206.87 and a 1-year high of $406.09. The business has a fifty day moving average price of $234.55 and a 200-day moving average price of $256.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market capitalization of $27.70 billion, a P/E ratio of 16.23, a P/E/G ratio of 1.62 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same quarter in the previous year, the business earned $7.23 earnings per share. The company's revenue was up 8.4% on a year-over-year basis. Equities analysts forecast that Humana will post 16.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC boosted its stake in Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co bought a new stake in shares of Humana in the 1st quarter valued at approximately $34,000. Garde Capital Inc. bought a new stake in shares of Humana in the 1st quarter valued at approximately $36,000. Zions Bancorporation National Association UT bought a new stake in shares of Humana in the 1st quarter valued at approximately $37,000. Finally, Transce3nd LLC bought a new stake in shares of Humana in the 4th quarter valued at approximately $38,000. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.